UK markets closed
  • FTSE 100

    +69.48 (+0.85%)
  • FTSE 250

    +257.89 (+1.27%)
  • AIM

    +5.43 (+0.69%)

    -0.0028 (-0.23%)

    +0.0096 (+0.76%)
  • Bitcoin GBP

    +2,357.94 (+4.53%)
  • CMC Crypto 200

    +47.50 (+3.41%)
  • S&P 500

    +62.68 (+1.17%)
  • DOW

    +130.50 (+0.34%)

    +0.18 (+0.23%)

    +18.30 (+0.79%)
  • NIKKEI 225

    -258.08 (-0.66%)

    -238.50 (-1.31%)
  • DAX

    +249.10 (+1.36%)
  • CAC 40

    +77.39 (+0.99%)

Insider Traders Lose US$91k As Shield Therapeutics Drops

The recent price decline of 11% in Shield Therapeutics plc's (LON:STX) stock may have disappointed insiders who bought US$122.0k worth of shares at an average price of US$0.061 in the past 12 months. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$31.0k, which is not what they expected.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Shield Therapeutics

Shield Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Non Executive Chairman Hans-Peter Hasler for UK£122k worth of shares, at about UK£0.061 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being UK£0.015). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Hans-Peter Hasler was the only individual insider to buy during the last year.


The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!


There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of Shield Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Based on our data, Shield Therapeutics insiders have about 2.7% of the stock, worth approximately UK£331k. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We consider this fairly low insider ownership.

What Might The Insider Transactions At Shield Therapeutics Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Shield Therapeutics insiders are doubting the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 4 warning signs for Shield Therapeutics (of which 1 shouldn't be ignored!) you should know about.

Of course Shield Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.